Holen Sie sich die Stockscreener-App
24.43
1.69%
-0.42
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$24.85
Offen:
$24.33
24-Stunden-Volumen:
117.62M
Relative Volume:
2.06
Marktkapitalisierung:
$138.90B
Einnahmen:
$62.79B
Nettoeinkommen (Verlust:
$9.84B
KGV:
14.24
EPS:
1.7156
Netto-Cashflow:
$10.38B
1W Leistung:
-0.89%
1M Leistung:
-7.00%
6M Leistung:
+7.20%
1J Leistung:
-11.03%
1-Tages-Spanne:
$24.11
$24.63
1-Wochen-Bereich:
$24.11
$25.20
52-Wochen-Spanne:
$20.91
$27.69
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Vergleichen Sie PFE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
24.43 | 141.29B | 62.79B | 9.84B | 10.38B | 1.7156 |
|
LLY
Lilly Eli Co
|
924.37 | 839.03B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
186.57 | 450.47B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
219.16 | 387.13B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
126.35 | 242.86B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
86.28 | 212.91B | 63.90B | 19.05B | 13.05B | 7.5596 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Pfizer, Metsera Enter Merger Agreement as Danish Rival Novo Nordisk Bows Out - MarketScreener
Key facts: Pfizer to acquire Metsera for over $10B; Novo Nordisk stands firm - TradingView
Pfizer wins $10 billion bidding war for obesity drug developer - New York Post
Novo’s CEO Turns to Next Targets After Losing Metsera to Pfizer - MSN
Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo Nordisk - Yahoo Finance
Pfizer wins bidding war for Metsera with $10B offer - BioPharma Dive
Pfizer acquires Metsera for $10 billion and targets the obesity drug market - MarketScreener
Pfizer clinches $10 billion Metsera deal, outbidding Novo Nordisk - TradingView
Pfizer To Buy Metsera In Deal Valued Up To $10 Billion - Pulse 2.0
2 No-Brainer Dividend Stocks to Buy With $100 in November - The Motley Fool
Pfizer wins $10B bidding war for obesity drug developer Metsera in major pharmaceutical acquisition - Fox Business
Pfizer wins $10 billion Metsera bidding war as Novo Nordisk exits - Yahoo Finance
Pfizer and Metsera Reach Deal Expected to Top $10 Billion - The Wall Street Journal
Pfizer to Acquire Obesity Drug Start-Up Metsera in $10 Billion Deal - The New York Times
Novo Nordisk gives up battle for Metsera as Pfizer inks $10B deal - Seeking Alpha
Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer - Seeking Alpha
Pfizer Wins Metsera Bidding War Over Novo With Final $10B Price Tag - BioSpace
Pfizer Sweetens Its Offer for Metsera in Bidding War Against Novo - MSN
Pfizer to Acquire Metsera in $10 Billion Weight-Loss Drug Deal, Surpassing Novo Nordisk - Analytics Insight
Pfizer to Buy Metsera for $10 Billion, Capping Bidding War - Bloomberg.com
Metsera to accept Pfizer after call from US antitrust regulators - MLex
Pfizer seals $10bn deal for Metsera as Novo Nordisk exits race - Nikkei Asia
Pfizer Prevails in Obesity Biotech Battle, Secures Metsera Over Novo Nordisk - FXLeaders
Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance - Benzinga
Pfizer acquires Metsera in $10 billion deal after competitive bidding with Novo Nordisk - MSN
Pfizer Wins! Acquires Metsera for $10 Billion, Outbidding Novo-Nordisk A/S - 富途牛牛
Pfizer sweetens offer for Metsera in bidding war against Novo, Bloomberg News reports - 1470 & 100.3 WMBD
Metsera accepts Pfizer's $10 billion bid in ongoing M&A battle - The Economic Times
Metsera says Pfizer to buy Metsera for up to $86.25 per share - MarketScreener
Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer - MarketScreener
Pfizer sweetens offer for Metsera in bidding war against Novo - The Edge Malaysia
Metsera enters merger agreement with Pfizer - TradingView
Pfizer sweetens its offer for Metsera in bidding war against NovoBloomberg news - MarketScreener
Pfizer wins $10 billion bidding war for Metsera as Novo Nordisk exits - MarketScreener
Spurned Pfizer Turns To Antitrust Law To Reclaim Biotech - Law360
Pfizer, Novo Nordisk bidding war is just the latest escalation of a lucrative GLP-1 race - Healthcare Brew
Pfizer, Novo risk overpaying in Metsera chase - Axios
Metsera's complex choice between Novo and Pfizer - Axios
“Pfizer (PFE) Beat The Numbers And People Just Yawned,” Says Jim Cramer - MSN
Pfizer Discusses Drug Pricing Deal, Metsera Buyout Dispute on Q3 Call - Zacks Investment Research
Novo CEO Fires Back at Pfizer From White House: ‘Put Your Hand in Your Pocket’ - BioSpace
Jim Cramer Says Pfizer “Will Continue to Sell at Eight Times Earnings” - Insider Monkey
Novo Nordisk Sweetens Bid for Obesity Drug Startup Metsera - Bloomberg.com
Pfizer Matches Novo's $10B Metsera Bid, And Other Rumors - Law360
Jim Cramer Highlights the Woes of Pfizer and the Drug Sector - Insider Monkey
Novo Nordisk CEO Challenges Pfizer to Raise its Bid for Metsera - Bloomberg.com
Novo CEO says its bid for Metsera is higher - Reuters
Pfizer: The Storm Has Passed — Tailwinds Ahead (NYSE:PFE) - Seeking Alpha
Pfizer matching Novo Nordisk's $10B bid for obesity drug maker Metsera after legal setback - The Business Journals
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.70%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):